MARKET

KTTA

KTTA

Pasithea Therapeutics Corp
NASDAQ
1.160
-0.010
-0.85%
Pre Market: 1.170 +0.01 +0.86% 08:33 12/05 EST
OPEN
1.150
PREV CLOSE
1.170
HIGH
1.208
LOW
1.110
VOLUME
67.56K
TURNOVER
0
52 WEEK HIGH
3.850
52 WEEK LOW
0.2810
MARKET CAP
25.98M
P/E (TTM)
-0.2226
1D
5D
1M
3M
1Y
5Y
1D
3 Penny Stocks to Watch Now, 12/2/25
TipRanks · 2d ago
Pasithea Therapeutics Completes $60M Public Offering
TipRanks · 3d ago
PASITHEA THERAPEUTICS ANNOUNCES CLOSING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK
Reuters · 3d ago
Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Dow Jones · 3d ago
Insider Buying Spree at Pasithea Therapeutics: Top Executives Invest Big!
TipRanks · 3d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 3d ago
Pasithea Therapeutics Director Lawrence Steinman Reports Acquisition of Common Shares
Reuters · 4d ago
Pasithea Therapeutics Form4 Filing Shows CEO Tiago Marques Bought 33,333 Shares At An Average Price Of $0.75/Share
Benzinga · 4d ago
More
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTA stock methods without spending real money on the virtual paper trading platform.